Every year a 2012 statement made by Phil Hagerman, RPh, the CEO at Diplomat, becomes a little truer: Specialty is pharmacy.
This past year has seen a plethora of new drug approvals, continued consolidation, specialty drug spending concerns and narrowing specialty channels as the various stakeholders—pharmacies, health systems, pharmacy benefits managers and health plans—battle for control of the specialty market and the patient, according to three industry veterans